This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Magee, W. C.
Right arrow Articles by Evans, D. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Magee, W. C.
Right arrow Articles by Evans, D. H.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2005, p. 3153-3162, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3153-3162.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Mechanism of Inhibition of Vaccinia Virus DNA Polymerase by Cidofovir Diphosphate

Wendy C. Magee,1 Karl Y. Hostetler,2 and David H. Evans1*

Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, The University of Alberta, Edmonton, Alberta T6G 2H7, Canada,1 San Diego VA Healthcare System, School of Medicine, University of California, San Diego, La Jolla, California 92093-06762

Received 10 January 2005/ Returned for modification 12 April 2005/ Accepted 17 May 2005

Cidofovir (CDV) is a broad-spectrum antiviral agent that has been approved for clinical use in the treatment of cytomegalovirus retinitis. It has also been used off label to treat a variety of other viral infections, including those caused by orf and molluscum contagiosum poxviruses. Because it is a dCMP analog, CDV is thought to act by inhibiting viral DNA polymerases. However, the details of the inhibitory mechanism are not well established and nothing is known about the mechanism by which the drug inhibits poxvirus DNA polymerases. To address this concern, we have studied the effect of the active intracellular metabolite of CDV, CDV diphosphate (CDVpp), on reactions catalyzed by vaccinia virus DNA polymerase. Using different primer-template pairs and purified vaccinia virus polymerase, we observed that CDV is incorporated into the growing DNA strand opposite template G's but the enzyme exhibits a lower catalytic efficiency compared with dCTP. CDV-terminated primers are also good substrates for the next deoxynucleoside monophosphate addition step, but these CDV + 1 reaction products are poor substrates for further rounds of synthesis. We also noted that although CDV can be excised from the primer 3' terminus by the 3'-to-5' proofreading exonuclease activity of vaccinia virus polymerase, DNAs bearing CDV as the penultimate 3' residue are completely resistant to exonuclease attack. These results show that vaccinia virus DNA polymerase can use CDVpp as a dCTP analog, albeit one that slows the rate of primer extension. By inhibiting the activity of the proofreading exonuclease, the misincorporation of CDV could also promote error-prone DNA synthesis during poxvirus replication.


* Corresponding author. Mailing address: Department of Medical Microbiology and Immunology, Faculty of Medicine and Dentistry, The University of Alberta, Edmonton, AB T6G 2H7, Canada. Phone: (780) 492-2308. Fax: (780) 492-7521. E-mail: devans{at}ualberta.ca.


Antimicrobial Agents and Chemotherapy, August 2005, p. 3153-3162, Vol. 49, No. 8
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.8.3153-3162.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.




This article has been cited by other articles:

  • Jesus, D. M., Costa, L. T., Goncalves, D. L., Achete, C. A., Attias, M., Moussatche, N., Damaso, C. R. (2009). Cidofovir Inhibits Genome Encapsidation and Affects Morphogenesis during the Replication of Vaccinia Virus. J. Virol. 83: 11477-11490 [Abstract] [Full Text]  
  • Gammon, D. B., Evans, D. H. (2009). The 3'-to-5' Exonuclease Activity of Vaccinia Virus DNA Polymerase Is Essential and Plays a Role in Promoting Virus Genetic Recombination. J. Virol. 83: 4236-4250 [Abstract] [Full Text]  
  • McSharry, J. J., Deziel, M. R., Zager, K., Weng, Q., Drusano, G. L. (2009). Pharmacodynamics of Cidofovir for Vaccinia Virus Infection in an In Vitro Hollow-Fiber Infection Model System. Antimicrob. Agents Chemother. 53: 129-135 [Abstract] [Full Text]  
  • Gammon, D. B., Snoeck, R., Fiten, P., Krecmerova, M., Holy, A., De Clercq, E., Opdenakker, G., Evans, D. H., Andrei, G. (2008). Mechanism of Antiviral Drug Resistance of Vaccinia Virus: Identification of Residues in the Viral DNA Polymerase Conferring Differential Resistance to Antipoxvirus Drugs. J. Virol. 82: 12520-12534 [Abstract] [Full Text]  
  • Magee, W. C., Aldern, K. A., Hostetler, K. Y., Evans, D. H. (2008). Cidofovir and (S)-9-[3-Hydroxy-(2-Phosphonomethoxy)Propyl]Adenine Are Highly Effective Inhibitors of Vaccinia Virus DNA Polymerase When Incorporated into the Template Strand. Antimicrob. Agents Chemother. 52: 586-597 [Abstract] [Full Text]  
  • Hamilton, M. D., Nuara, A. A., Gammon, D. B., Buller, R. M., Evans, D. H. (2007). Duplex strand joining reactions catalyzed by vaccinia virus DNA polymerase. Nucleic Acids Res 35: 143-151 [Abstract] [Full Text]  
  • Kornbluth, R. S., Smee, D. F., Sidwell, R. W., Snarsky, V., Evans, D. H., Hostetler, K. Y. (2006). Mutations in the E9L Polymerase Gene of Cidofovir-Resistant Vaccinia Virus Strain WR Are Associated with the Drug Resistance Phenotype. Antimicrob. Agents Chemother. 50: 4038-4043 [Abstract] [Full Text]  
  • Andrei, G., Gammon, D. B., Fiten, P., De Clercq, E., Opdenakker, G., Snoeck, R., Evans, D. H. (2006). Cidofovir Resistance in Vaccinia Virus Is Linked to Diminished Virulence in Mice. J. Virol. 80: 9391-9401 [Abstract] [Full Text]